CNBC
08 Jun 2026, 09:40 UTC · 4h ago
Weight loss drug maker sinks 25% after new safety data spooks investors
CNBC
08 Jun 2026, 09:40 UTC · 4h ago
Story key points
4 claims · impact-rated
Zealand Pharma's experimental drug survodutide saw a 19% patient dropout rate due to gastrointestinal events compared to 2.9% for placebo. — High discontinuation rates due to side effects severely undermine the drug's safety profile and commercial viability.
-0.90Analysts from Citi stated that survodutide's adverse event levels are above what is considered commercially viable against competitors tirzepatide and semaglutide. — Loss of competitive positioning against established market leaders in the weight-loss sector reduces the company's future revenue potential.
-0.80Zealand Pharma shares plummeted as much as 26% following the release of the survodutide late-stage study data. — Immediate equity devaluation reflects the market's pricing in the increased risk of trial failure or limited market adoption.
-0.50Continue reading
6 related stories
Top 2 movers · tap to explore
Survodutide successfully met its key targets in the late-stage study despite the tolerability issues. — Proof of efficacy provides some baseline value, though it is heavily outweighed by the safety concerns.
+0.20Ticker attribution
Model heads
Shares plummeted due to high patient dropout rates and safety concerns regarding its experimental drug survodutide.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
WSJ
4h ago
